Skip to main content Back to Top


Sincalide to Be Available Again

Kate Traynor

Bracco Diagnostics Inc. announced yesterday that Kinevac, the company’s injectable cholecystopancreatic–gastrointestinal hormone peptide product, will be back on the market starting Dec. 16.

Kinevac, or sincalide for injection, is a diagnostic aid used in functional tests of the gallbladder, pancreas, and intestinal tract.

The product has been on back order since September 2001. Bracco attributed the supply problem to "unexpected manufacturing interruptions unrelated to the product."

According to the company, technology transfer issues and a change in manufacturers forced Bracco to seek approval from the Food and Drug Administration (FDA) before reintroducing the product. Bracco reported that FDA approved the supplemental new drug application for sincalide on Nov. 27.